Oral · GLP-1 agonist
Ecnoglutide (XW004)
2 trials in this program. Source: ClinicalTrials.gov, as of July 1, 2026.
Distinct formulations of the same molecule
This molecule is developed in parallel as separate programs. They are not competing therapies (they share the same active drug) but differ by formulation, route, and developer. Trials below are labeled with their program code.
- All Ecnoglutide
- Ecnoglutide (XW003): Subcutaneous, Sciwind Biosciences
- Ecnoglutide (XW004): Oral, Sciwind Biosciences
- Ecnoglutide (VRB-101): Oral, Verdiva Bio
Trials
2
Active
1
Recruiting
1
Completed
1
Sites
2
Countries
2
Endpoints
13
Composite endpoints
1
Distinct sites and countries across this program's trials. A site running several of its trials counts once, matching the map.
Development
Where the program stands
Trials by phase
Trials by status
Evidence coverage
What this asset has been measured on
Endpoints grouped into outcome categories, ranked by how often they are measured across this asset's trials.
Most-measured metrics
Top 20 metrics across this asset's endpoints
2
1
1
1
1
1
Trials
Trials for XW004
Every trial for this program, with the same search, filters, and sort as the Trials tab.
2 of 2
| Asset / Population | Key I/E criterion | Evidence | ||||||
|---|---|---|---|---|---|---|---|---|
| NCT05184322XW004 To Evaluate the Safety, Tolerability, PK, and PD of Oral Ecnoglutide Tablet in Healthy Adults | Ecnoglutide (XW004) Healthy volunteers, Obesity / overweight | BMI 22-32 | Ph 1 | Completed | 1 | Jul 2024 | — | |
| NCT07243171A Phase Ib/IIa Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Oral Ecnoglutide Tablets in Chinese Participants With Overweight or Obesity | Ecnoglutide (XW004) Obesity / overweight | BMI 24-35 | Ph 1/2 | Recruiting | 1 | Aug 2026 | — |